Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 18, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,124.3338 pence per share.
Material Changes
- Share Repurchase: The company purchased 2,665,000 ordinary shares on February 18, 2008.
- Share Cancellation: The repurchased shares were cancelled immediately.
- Treasury Holdings: Following this transaction, the company holds 504,194,158 shares in Treasury, representing 9.18% of total voting rights.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,492,155,767.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,492,155,767) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (504,194,158) and its percentage of voting rights (9.18%).
- Review the specific authorization from the May 23, 2007 Annual General Meeting regarding the share buyback program.